DIRS.INFO The most relevant business & tech news

☆ Abbott launches its first over-the-counter continuous glucose monitor in the U.S.
▼ + stars: | 2024-09-05 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +3 min

Abbott Laboratories announced Thursday its over-the-counter continuous glucose monitor Lingo is available in the U.S. starting at $49. These devices, called continuous glucose monitors, are small sensors that stick through the skin to measure real-time glucose levels. Continuous glucose monitors have served as tools for patients with diabetes, but Lingo is not intended for diabetes management. The company released its over-the-counter continuous glucose monitor geared toward this demographic in late August. The U.S. Food and Drug Administration approved Dexcom's Stelo in March, and it cleared two over-the-counter continuous glucose monitoring systems from Abbott in June.

Persons: Lingo, it's, Abbott, That's, Ben Fohner, Abbott's, Olivier Ropars, Ropars, Dexcom's Organizations: Abbott, CNBC, U.S . Food, Drug Administration, Dexcom's Stelo, Libre, Libre Rio Locations: U.S

☆ Cramer's Lightning Round: Lowe's is a buy
▼ + stars: | 2024-07-30 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Borr Drilling's year-to-date stock performance. Stock Chart Icon Stock chart icon Blackstone's year-to-date stock performance. Stock Chart Icon Stock chart icon Dexcom's year-to-date stock performance. Stock Chart Icon Stock chart icon Lowe's year-to-date stock performance. Stock Chart Icon Stock chart icon Joby Aviation's year-to-date stock performance.

Persons: Borr, Blackstone, Abbott, Edwards Lifesciences, Edwards, Joby, Marvell, Matt Murphy, Jim Cramer's Organizations: Borr, Boston Scientific, Joby, Marvell Technology, Marvell

☆ Dexcom shares plunge more than 40%, head for worst day on record
▼ + stars: | 2024-07-26 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +4 min

Dexcom shares sank more than 40% on Friday and headed for their worst day ever after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. The stock fell $45.38 to $62.47 as of early afternoon, wiping out about $18 billion in market cap. Prior to Friday, the biggest drop came in September 2017, when the shares plunged 33% in a day. Dexcom held its stock market debut in 2005. With Friday's selloff, Dexcom shares are down almost 50% for the year, while the S&P 500 is up 15%.

Persons: Dexcom, Kevin Sayer, we've, Sayer, JPMorgan's Robbie Marcus, Marcus, Jereme Sylvain, Sylvain, William Blair, Leerink, Stelo, Friday's Organizations: JPMorgan, U.S . Food, Drug Administration

☆ Dexcom shares plummet more than 30% after company lowers fiscal year guidance
▼ + stars: | 2024-07-25 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +2 min

Shares of Dexcom tumbled more than 35% in extended trading Thursday after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. The company reported net income of $143.5 million, up from the $115.9 million it reported during the same period last year. Dexcom updated its full fiscal year guidance to reflect expected revenue between $4 billion and $4.05, which is down from the $4.20 billion to $4.35 billion it forecast last quarter. "While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," Dexcom CEO Kevin Sayer said in the release. In March, the company announced its new over-the-counter CGM called Stelo had been cleared for use by the U.S. Food and Drug Administration.

Persons: LSEG, Dexcom, Kevin Sayer, Stelo Organizations: LSEG Revenue, U.S . Food, Drug Administration

☆ Stocks making the biggest moves after hours: Dexcom, Coursera, Deckers Outdoor and more
▼ + stars: | 2024-07-25 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Revenue in the second quarter missed analysts' expectations, coming in at $1 billion versus consensus estimates of $1.04 billion, per LSEG. Boston Beer Company – The maker of Twisted Tea and Samuel Adams slid 5% after second quarter results missed the Street's estimates. The company reported adjusted earnings of $3 per share, excluding items, on revenue of $2.8 billion in the second quarter. Juniper posted adjusted earnings of 31 cents per share and revenue of $1.19 billion in the second quarter. That came up short against analysts' estimates of 44 cents per share in earnings and $1.25 billion in revenue, per LSEG.

Persons: Samuel Adams, Boston Beer, Coursera, Juniper, —, Darla Mercado Organizations: Revenue, Boston Beer Company, Boston, Mohawk Industries, FactSet, Juniper Networks

☆ Signos uses a glucose monitor patch and AI to help you eat healthier. Here's what it's like
▼ + stars: | 2024-03-09 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +13 min

SignosFounded in 2018, Signos uses continuous glucose monitors, or CGMs, and an artificial intelligence-powered app to help people better understand their metabolisms. But Signos' CGM system is meant for average consumers, so it is not intended for diabetes management. The Signos app walked me through the process step by step, offering a one-minute video and a series of GIFs I could watch. Another activity had me try and guess what I thought my glucose levels were at different points throughout the day. After eating a meal, I would often get a "Fast Rise" notification from my Signos app, which indicates that a glucose spike is occurring.

Persons: Ashley Capoot, I've, Signos, Dexcom, Sharam Fouladgar, you've, it's Organizations: CNBC, Abbott Laboratories, Centers for Disease Control, U.S . Food, Drug Administration, Dexcom Ventures, Bluetooth Locations: U.S, Mercer

☆ Dexcom announces its first-ever over-the-counter CGM Stelo has been cleared by the FDA
▼ + stars: | 2024-03-05 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +3 min

This means Stelo will be accessible to people who do not have insurance coverage for CGMs, Dexcom said. There are more than 25 million Type 2 diabetes patients in the U.S. that do not use insulin, according to the release from Dexcom. Dexcom shared Stelo's name, as well as the fact that the device had been submitted to the FDA for review in February. Jake Leach, chief operating officer at Dexcom, told CNBC in February that Stelo will have its own unique platform and branding. Leach said as Dexcom is able to demonstrate the benefits of Stelo, the company believes insurance companies will eventually pay for it.

Persons: Dexcom, it's, Dr, Jeff Shuren, Jake Leach, Stelo, It's, Leach Organizations: U.S . Food, Drug Administration, FDA's Center, Devices, Radiological, FDA, CNBC, CNBC PRO Locations: U.S

☆ Alibaba, ASML and more: Jefferies reveals its 'highest-conviction' stocks to buy — and one has 118% upside
▼ + stars: | 2024-02-01 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Investment bank Jefferies has revealed its top stock picks that are exposed to major themes like innovation, new products, and emerging markets. The investment bank forecasts Prudential shares will rise 118% to 18,000 British pence over the next 12 months. The investment bank expects Hong Kong-listed shares of Alibaba to rise to 128 Hong Kong dollars ($17), which implies an 84% upside potential. The investment bank expects shares to rise 57% over the next 12 months. The investment bank believes ASML's current valuation of 33 times forward earnings is too low since it forecasts 49% earnings growth over the next two years.

Persons: Jefferies, Prudential Jefferies, Prudential's, Anil Wadhwani, Eddie Wu, Wu, Alibaba's, Joe Dickerson, Dickerson, — CNBC's Michael Bloom Organizations: Prudential, Jefferies, Hong, U.S, HSBC Jefferies, HSBC, ASML Semiconductor, DexCom Locations: U.K, Asia, China, India, Africa, Hong Kong, Alibaba

☆ As Ozempic and Wegovy take off, this tech startup just raised $20 million to tackle weight loss with data
▼ + stars: | 2023-10-24 | by ( Ashley Capoot | ) www.cnbc.com time to read: +6 min

Weight loss has always been big business, but it's exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs. "Whether you have five pounds to lose or 100, we want to make sure we're able to help everybody," Sharam Fouladgar-Mercer, Signos' co-founder and CEO, told CNBC in an interview. Fouladgar-Mercer said he created the company in 2018 partly because of his own struggle to manage weight throughout his life. Users can also integrate sleep data, heart rate data, and exercise data from their Apple Watch to personalize their profile even more. Fouladgar-Mercer said Signos can work well alongside Ozempic and Wegovy from Novo Nordisk and other GLP-1 treatments.

Persons: Signos, Mercer, it's, It's, GLP Organizations: Cheyenne Ventures, GV, Google Ventures, Dexcom Ventures, CNBC, Signos, U.S . Food, Drug Administration, Apple Watch, Abbott Laboratories, U.S, Novo Nordisk, Nordisk's Locations: Mercer, Novo, Europe, Fouladgar, America

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ Silicon Valley Bank signed exclusive banking deals with some clients, leaving them unable to diversify
▼ + stars: | 2023-03-12 | by ( Rohan Goswami | ) www.cnbc.com time to read: +4 min

All required the companies to open or maintain bank accounts with SVB and use the firm for all or most of their banking services. Silicon Valley Bank had exclusivity clauses with some of its clients, limiting their ability to tap banking services from other institutions, SEC filings show. Upstart held its IPO in 2020, two years after DocuSign's debut. As with Upstart, SVB set strict limits on the value and type of accounts that Sprout could hold elsewhere. The contract included an exception for international bank accounts but required that Limelight use only SVB's business credit cards.

Search resuls for: "Dexcom's"

11 mentions found